

Data Featured at EULAR 2026

Johnson&Johnson

European Alliance of Associations for Rheumatology Congress

London, UK
3-6 June 2026

Johnson & Johnson-sponsored nipocalimab studies

Abstract number	Title	Presentation time (BST)
Sjögren's disease (SjD)		
DAHLIAS data abstracts		
OP0131	Biomarker-driven insights to clinical response in DAHLIAS: a nipocalimab trial for Sjögren's disease	Oral presentation Wednesday, 3 June 17:40 - 17:50
POS0285*	Clinically relevant anti-vaccine and virus antibodies in patients with Sjögren's disease treated with nipocalimab: post-hoc analysis of the DAHLIAS study	Poster tour Friday, 5 June 14:12 - 14:18 BST
B1488-PARE	Assessing the patient experience of nipocalimab: exit interviews from the Phase 2 randomized placebo-controlled study in Sjogren's disease	Abstract book only
SWIMM3 study abstract		
AB0969	Incidence comorbidities and causes of mortality in patients with Sjögren's disease in Swedish population between 2006-2022	Abstract book only
Systemic lupus erythematosus (SLE)		
JASMINE study abstracts		
LB0007	Nipocalimab in SLE: first-in-class efficacy and safety results demonstrating proof of concept for FcRn blockade from the Phase 2 JASMINE-SLE study	Late Breaker Saturday, 6 June 13:00-13:10
GLADEL 2.0 cohort data abstracts		
OP098*	Cluster analysis of socioeconomic and environmental determinants modifying activity, chronicity and clinical manifestations of systemic lupus erythematosus in the GLADEL 2.0 cohort	Oral presentation Wednesday, 3 June 17:30 - 17:40 BST
POS1356	Intravenous cyclophosphamide versus mycophenolate mofetil for induction therapy in incident lupus nephritis: data from a multi-ethnic, multinational Latin American cohort (GLADEL 2.0)	Poster View Saturday, 6 June 10:15 - 11:15
AB1121	Pregnancy and obstetric outcomes in systemic lupus erythematosus: insights from the GLADEL 2.0 cohort	Abstract book only
AB1111*	Risk factors for pulmonary manifestations in GLADEL 2.0, a systemic lupus erythematosus Latin American cohort	Abstract book only
AB1134*	Feasibility of extrarenal systemic lupus erythematosus disease modification in GLADEL 2.0, a Latin American cohort	Abstract book only
LupusNet data abstracts		
POS0731	Age at onset and its association with damage accrual in systemic lupus erythematosus (SLE): insights from 5 registries in the Lupus Federated Data Network	Poster view Thursday, 4 June 9:30 - 10:30
POS1055	Systemic treatment patterns in SLE: associations with disease severity and organ-specific activity across 5 registries in the lupus federated data network	Poster view Friday, 5 June 16:00 - 17:00
AB1146*	Regional variability in SLE damage accumulation by disease activity across the Lupus Federated Data Network	Abstract book only

*Encore abstract

AB1103*	Customized therapy for SLE: how disease severity influences the use of corticosteroids and biologics in patients with SLE in the Lupus Federated Data Network and a U.S. claims database	Abstract book only

Sjögren's syndrome / systemic lupus erythematosus / rheumatoid arthritis		
RWE study abstract		
POS1166	Treatment patterns before and during pregnancy in women with Sjögren's syndrome, systemic lupus erythematosus, or rheumatoid arthritis: a nationwide population-based register study in Sweden	Poster view Saturday, 6 June 10:15 - 11:15

Johnson & Johnson-sponsored guselkumab studies

Abstract number	Title	Presentation time (BST)
Psoriatic arthritis (PsA)		
APEX data abstracts		
OP075	Structural damage progression and clinical response to guselkumab in participants with active and erosive psoriatic arthritis: post hoc analysis at Week 24 of the Phase 3b, randomized, double-blind, placebo-controlled APEX study	Oral presentation Wednesday, 3 June 17:40 - 17:50
POS0477	Effects of guselkumab on patient-reported outcomes in biologic-naïve participants with active and erosive psoriatic arthritis: results through Week 24 of the Phase 3b, randomized, double-blind, placebo-controlled APEX study	Poster view Wednesday, 3 June 15:30 - 16:30
POS0480*	Guselkumab response and inhibition of structural damage progression in active psoriatic arthritis across APEX participant subgroups	Poster view Wednesday, 3 June 15:30 - 16:30
POS0471	Psoriatic skin and nail outcomes with guselkumab treatment in participants with active and erosive psoriatic arthritis: results through Week 24 of the Phase 3b, randomized, double-blind, placebo-controlled APEX study	Poster view Wednesday, 3 June 15:30 - 16:30
AB0754	Pharmacodynamic biomarkers in biologic-naïve participants with active and erosive psoriatic arthritis: results through Week 48 from the Phase 3 APEX study	Abstract book only
AB0691	Efficacy of guselkumab assessed by composite indices in participants with active and erosive psoriatic arthritis: analyses through Week 24 of the Phase 3b, randomized, double-blind, placebo-controlled APEX study	Abstract book only
AB0731	Achievement of cDAPSA low disease activity/remission and association with structural damage progression in guselkumab-treated participants with active and erosive psoriatic arthritis: post hoc analysis through Week 48 of the Phase 3b, randomized, double-blind, placebo-controlled APEX study	Abstract book only

PsABIOnd study abstract		
POS0045	Persistence, effectiveness, safety, and patient reported impact of guselkumab and IL-17 inhibitors in psoriatic arthritis: full population results of the PsABIOnd global observational study over 12 months	Poster tour Wednesday, 3 June 15:30 - 15:36

*Encore abstract

PsA study abstract		
POS0084	Axial–peripheral immune divergence at human entheseal sites revealed by single-cell transcriptomics	Poster tour Thursday, 4 June 9:54 - 10:00

DISCOVER COSMOS study abstract		
POS0491	Joint disease activity trajectories in participants with active psoriatic arthritis treated with guselkumab: a Bayesian analysis of three Phase 3, randomized, controlled studies	Poster view Wednesday, 3 June 15:30 - 16:30

MANHATTAN study abstract		
AB0700	Second-line treatment with guselkumab or TNFi in psoriatic arthritis patients previously treated with a first-line TNFi: real-world efficacy results up to Week 76 from the Manhattan study	Abstract book only

SOLSTICE study abstract		
POS0492*	Efficacy and safety of guselkumab in participants with active psoriatic arthritis and inadequate response/intolerance to one prior tumor necrosis factor inhibitor through 1 year of the SOLSTICE study	Poster view Wednesday, 3 June 15:30 - 16:30

CorEvitas study abstract		
AB0739*	12-month persistence and multi-domain effectiveness of guselkumab in adults with active psoriatic arthritis: real-world data from the PPD CorEvitas psoriatic arthritis/spondyloarthritis registry	Abstract book only

IQVIA study abstract		
AB0737*	Real-world on-label treatment persistence through 24 months in biologic-naïve and biologic-experienced patients with psoriatic arthritis: comparison of guselkumab versus targeted synthetic disease-modifying antirheumatic drugs	Abstract book only

PsD/IBD study abstract		
OP0247*	Pregnancy outcomes in maternal exposure to guselkumab: review of cases reported to the company global safety database	Oral presentation Thursday, 4 June 9:05 - 9:15

Johnson & Johnson-sponsored icotrokinra studies

Abstract number	Title	Presentation time (BST)
Plaque psoriasis (PsO) and psoriatic arthritis (PsA)		
ICONIC-LEAD | ICONIC-ADVANCE 1 & 2 data abstract		
POS0052	Icotrokinra, a targeted oral peptide, in participants with moderate-to-severe plaque psoriasis and psoriatic arthritis: results from a pooled analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 trials	Poster tour Wednesday, 3 June 16:12 - 16:18
Psoriasis		
ICONIC-LEAD | TOTAL | ADVANCE 1 & 2 data abstract		
AB0618*	Treatment of plaque psoriasis involving high-impact sites with icotrokinra, a targeted oral peptide: pooled analyses of 4 Phase 3 placebo-controlled trials	Abstract book only

*Encore abstract

ENCOMPASS study abstract		
AB0616*	Unmet needs and disease burden: perspectives from adults with psoriasis and clinicians treating psoriasis in the United States	Abstract book only

Johnson & Johnson-sponsored JNJ-4804 studies

Abstract number	Title	Presentation time (BST)
Psoriatic arthritis (PsA)		
AFFINITY study abstracts		
OP0186	Effect of guselkumab and golimumab combination therapy on magnetic resonance imaging-detected inflammation and damage in phalangeal joints of the hands and feet and entheses of the heels among participants with active psoriatic arthritis: findings from the Phase 2a AFFINITY study	Oral presentation Thursday, 4 June 9:15 - 9:25
POS0479	Biomarker-driven insights from the Phase 2a AFFINITY study evaluating guselkumab + golimumab combination therapy versus guselkumab monotherapy in psoriatic arthritis	Poster view Wednesday, 3 June 15:30 - 16:30

Johnson & Johnson-sponsored ustekinumab studies

Abstract number	Title	Presentation time (BST)
Psoriatic arthritis (PsA)		
PSUMMIT-Jr study abstract		
POS0502	Efficacy and safety of subcutaneous ustekinumab in pediatric participants with active juvenile psoriatic arthritis: results of the open-label, Phase 3 PSUMMIT-Jr study through Week 52	Poster View Wednesday, 3 June 15:30 - 16:30

Johnson & Johnson-sponsored AI studies

Abstract number	Title	Presentation time (BST)
Psoriatic arthritis (PsA)		
Sharp.AI study abstract		
POS0668	Sharp.AI: Longitudinal AI-based evaluation of radiographic progression in psoriatic arthritis	Poster View Thursday, 4 June 9:30 - 10:30

Sharp.Enhance study abstract		
AB0085	From expert annotations to computer vision-enabled quantitative radiographic endpoints for structural joint damage	Abstract book only

Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

*Encore abstract